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Translational relevance
HER2 is an interesting therapeutic target because it is overexpressed in cancers including breast, ovarian and gastric. There is a need for strategies to overcome resistance to HER2-targeted therapies for metastatic breast cancer (BC). SdAbs are a promising platform for both imaging and targeted therapy. The 68 Ga-labeled HER2-targeting variant was successfully evaluated before in a first clinical study in BC patients to non-invasively detect HER2 expression using PET. We describe here a novel  
Introduction
The Human Epidermal Growth Factor Receptor type 2 (HER2) is overexpressed in multiple human cancers including breast, ovarian, colorectal and urothelial carcinomas (1) . Its incidence in breast cancer (BC) is about 20-30% and is often associated with a higher recurrence rate and a shorter time to relapse (2, 3) . Upon BC diagnosis, 10% of women have metastatic disease, which is considered incurable. Treatment goals are mainly focused on prolonging overall survival (OS) and progression free survival (PFS). Therapies targeting HER2 can significantly impact the outcome of HER2 + metastatic BC (4): since the introduction of anti-HER2 drugs to the standard of care, OS has increased significantly. However, emerging resistance to trastuzumab and the kinase-inhibitor lapatinib are frequently observed. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, combines the anti-tumor effects of trastuzumab with those of the microtubule-inhibitory agent DM1, a cytotoxic agent that is released within target cells. T-DM1 has shown therapeutic potential for the treatment of advanced BC patients that progressed after combined treatment with trastuzumab and taxane (5) . Unfortunately, most patients eventually progress on T-DM1 due to acquired resistance (6) .
Combining versatile HER2-therapies that can circumvent drug resistance are therefore of high importance (7) .
Targeted radionuclide therapy (TRNT) deploys therapeutic radiolabeled molecules like monoclonal antibodies (mAbs), mAb-fragments, peptides or synthetic proteins that interact with tumor-associated membrane proteins, and targets both the primary tumor site as well as metastases. The integration of molecular imaging can assist to predict successful TRNT. This theranostic approach aims to include an identical imaging compound (8) to predict targeting and potential toxicity to healthy tissues. Currently, one mAb-based TRNT agent is commercially used, i.e. the anti-CD20 mAb 90 Y-ibritumomab for treating B cell non-Hodgkin lymphoma (9) (10) (11) . Peptide receptor radionuclide therapy (PRRNT) shows efficacy in patients with neuroendocrine tumors (12) and is currently also being investigated in prostate and pancreatic carcinomas (12, 13) .
Camelid single-domain antibody-fragments (sdAbs), also referred to as VHHs or nanobodies®, may solve some of the issues related to the use of other targeting vehicles such as mAbs for theranostic application. SdAbs (10-15 kDa) are antigen-binding fragments that are derived from Camelidae heavy-chain-antibodies and have advantageous characteristics compared to mAbs and their derived fragments for in vivo targeting (14 (8, (15) (16) (17) . We recently reported a first-inhuman PET study with 68 Ga-labeled anti-HER2 sdAb 2Rs15d for breast cancer imaging (18, 19) .
2Rs15d was initially selected because of its non-competing character with trastuzumab and pertuzumab for HER2-binding (20) and could therefore have its use as a therapeutic in tumors resistant to these agents. To this, 2Rs15d was previously applied as a vehicle for preclinical TRNT after labeling with 177
Lu (21) . Crucial for the success of future therapeutic sdAb-based applications are reducing kidney retention of radiolabeled sdAbs, which could otherwise lead to renal toxicity. Indeed, substantial retention of radioactivity in kidneys is observed after i.v.
injection of radiometal-sdAb conjugates (8, 17, 21) , leading us to shift our focus to the use of radiohalogens for labeling sdAbs.
Herein, we describe the generation of a theranostic anti-HER2 sdAb using the radiohalogen 131 I (T 1/2 =8.02 d, <E β (mean)> = 190keV, <E> = 364keV). 2Rs15d was radiolabeled with 131 I via the residualizing prosthetic group N-succinimidyl 4-guanodinomethyl-3-*Ibenzoate (*ISGMIB) (22) . The reason for selecting *ISGMIB was twofold: (i) this prosthetic group was designed to have rapidly clearing catabolites, which should help reduce kidney dose from small radiolabeled biomolecules that are filtered via kidneys (23); (ii) the high pKa of its guanidino group interferes with the transport of labeled catabolites out of lysosomes, thereby trapping the radioiodine in cancer cells (24) . The improved tumor targeting of a *ISGMIB-labeled anti-HER2 sdAb was first shown with 5F7GGC sdAb (25) . Unfortunately, 5F7GGC competes with trastuzumab for binding to domain IV on HER2 (25), thereby compromising its clinical translation and not offering solutions to certain HER2 treatment resistance mechanisms (7) . The goal of this study was to generate a potentially more clinically relevant theranostic drug by labeling the anti-HER2 sdAb 2Rs15d with 
131
ISGMIB.
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Materials and Methods
General
All reagents were purchased from Sigma-Aldrich except when noted. Sodium [ 131 I]iodide in 0.1N NaOH with a specific activity >185GBq/mg was purchased from Perkin-Elmer (Boston, MA, USA). All reagents used in cell culture experiments were purchased from Gibco BRL (Grand Island, NY, USA) except when noted. SdAbs were generated as described previously (18) .
HER2-targeting 2Rs15d, HER2-targeting but trastuzumab-competing 2Rb17c, and nontargeting R3B23 (control sdAb) were fully characterized previously (18, 20, 26) . Trastuzumab (Herceptin®) and pertuzumab (Perjeta®, Hoffmann-La Roche Ltd, Basel, Switzerland) were used as stated in the experiments.
Determination of the HER2-2Rs15d complex crystal structure
Protein purification, crystallization of the HER2-2Rs15d complex and structural determination were performed by PROTEROS (Planegg, Germany). Detailed methods for crystallization, data collection and structure determination are given in the Supplemental Materials and Methods and are summarized in Supplementary Table S1 . The crystallographic data for the HER2- fetal bovine serum, and a mixture of 100 U/mL penicillin and 0.1 mg/mL streptomycin (Invitrogen, Paisley, UK). Cells were grown in a humidified atmosphere with 5% CO 2 at 37°C.
Prior to use for in vitro and in vivo purposes, cells were detached using trypsin-EDTA. HER2- 9 lysed with 1M NaOH to determine the internalized fraction. All fractions were counted for radioactivity using an automated gamma counter.
Animal models
Normal male C57Bl/6 mice were used to assess blood clearance. Toxicity analysis was performed in normal male and female Swiss albino mice. Female CRL:Nu-FoxN1nu mice were implanted with a 60-day slow-release estrogen pellet, after which they were inoculated in the right hind leg with 1x10 7 BT474/M1 cells in 1/1 matrigel/cell culture medium. Tumors were grown to 284171 mm 3 for imaging and dissections, and to 5030 mm 3 for therapy. The same strain was also inoculated with 4x10 6 SKOV-3 cells in cell culture medium and grown until they reached 450100 mm 3 for imaging, and intraperitoneally (i.p.) inoculated with 0.5x10 6 SKOV-3.IP1 cells in case of therapy (29) . Tumor growth was measured using caliper or bioluminescence imaging after i.p. injection of 150 mg/kg Luciferin (30) . All animal protocols were approved by the ethical committee of the Vrije Universiteit Brussel (14-272-5). Organ-absorbed doses of 
Biodistribution of 
131
I-2Rs15d
The biodistribution data were time-integrated to obtain the residence time per gram tissue (21, 25) . Briefly, the area under the curve between 0 and 120 h was made using the trapezoid integration method. Next, the absorbed doses were calculated using S values for 131 I obtained from RADAR phantoms (Unit Density Spheres). The S value for a 1g sphere (0.0304
Gy.g/MBq.s) was used to calculate all organ doses. In parallel, an estimation of organ absorbed doses was performed by extrapolation to the adult female phantom with OLINDA 1.0 software using a voiding bladder interval of 1h. The calculations were based on time-activity curves to determine the number of disintegrations in organs. Organ doses and effective dose were calculated using the appropriate weighing factors.
Therapeutic efficacy of 
131
I-2Rs15d
In the first experiment, BT474/M1 tumor xenografted mice (n=6) received 5 i.v. injections 
Results
Determination of the HER2-2Rs15d complex crystal structure
The crystal structure of the HER2-2Rs15d complex reveals that the sdAb interacts with an epitope located on HER2 domain I. This is distinct from the HER2 sites recognized by trastuzumab and pertuzumab (Fig. 1A) and most other reported HER2 binders ( Supplementary   Fig. S1A-B) .
As expected, interactions with HER2 are mediated by 2Rs15d residues located in the complementarity determining regions (CDRs) however, an almost equal number of amino acids located in the framework regions (FRs) also contribute to HER2 recognition. Importantly, none of the 2Rs15d residues involved in HER2 binding are lysines ( Supplementary Fig. S1C ), the site of SGMIB-conjugation. A detailed description of the interactions between 2Rs15d and HER2 domain I is presented in Supplementary Fig. S1D and Supplementary Table S2 . 
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BT474/M1 and SKOV-3 cells, and trastuzumab-resistant JIMT-1 cells (in which HER2 domain IV is obscured by overexpressed MUC4) (28) .
Binding affinities to HER2 of 3.990.04 nM and 3.620.03 nM for 2Rs15d and  127 I-2Rs15d, were determined by SPR (Fig. 2B-C (Fig. 2D) . The non-competing character of unlabeled 2Rs15d with trastuzumab and pertuzumab was confirmed via SPR measurements (Fig. 1B-C) , and 
131
I-2Rs15d on BT474/M1 and SKOV-3 cells (Fig. 1D-E) .  (Fig. 1F-G) . These observations were confirmed by flow cytometry (Fig. 1H) . The binding affinity of  (Fig. 2E) . The cell-associated fraction of 
I-2Rs15d remained stable over time, ranging between 20-30% of initially bound activity (Fig. 2F ).
At 1h, 17.00±0.69% was membrane-bound and 9.13±2.37% was internalized. At 24h,
28.79±1.95% of 
131
I-2Rs15d remained cell associated of which about half was internalized and half bound to membrane.
Blood clearance and biodistribution of 
131
I-2Rs15d
Consecutive micro-SPECT/CT images in BT474/M1 (Fig. 3A) and SK-OV-3 (Fig. 3B) s.c. tumor xenografted mice were generated and quantified ( Fig. 3C and Supplementary Table S3) IA/cc after 4h, and to a value below 0.5% IA/cc after 24h, while the fraction in tumor remained 4.540.81% IA/cc after 4h and 2.501.22% IA/cc after 24h. Very low uptake values were measured for thyroid and muscle. Similar results were obtained with the SKOV-3 model, although lower tumor uptake was measured (2.310.22% IA/cc after 1h and 1.160.03% IA/cc after 24h), due to the lower HER2 expression compared to BT474/M1.
I-2Rs15d was cleared from blood in a biphasic manner (Fig. 4A) Fig. 5A . Patient organ-absorbed doses were estimated using OLINDA via extrapolation to the adult female phantom ( Table 1 ).
The effective dose for the adult female was 0.0273 mSv/MBq.
Therapeutic efficacy of 
131
I-2Rs15d
BT474/M1 xenografted mice receiving  
Discussion
About 20-30% of BCs overexpress HER2, resulting in a more aggressive phenotype with a poor prognosis. HER2-directed therapies increase OS; however a significant fraction of patients suffer from relapse and disease progression (4). Resistance to HER2-directed therapies occurs either through mechanisms at the HER2 target or through bypass signaling (7) . Trastuzumab resistance can occur through mutations to its HER2 epitope or the presence of truncated and isoforms of HER2 like p95HER2 (31) and D16 HER2 (32) . Moreover, co-expression of proteins like MUC-1 and -4 can prevent trastuzumab from binding HER2 (33, 34) . Mutations in the kinase domain of HER2 can lead to lapatinib resistance (35) . The cytotoxic effect of T-DM1 is dependent on the intracellular concentration of DM-1. Consequently, mechanisms that lead to impaired HER2-binding or receptor-mediated endocytosis will influence therapeutic efficacy significantly (6) . As more data emerge suggesting that combining versatile HER2-therapies can abolish drug resistance, novel strategies that target HER2 at multiple points become clinically important.
We generated a library of anti-HER2 sdAbs (20) from which 2Rs15d was selected as the lead compound based on its overall optimal properties including high affinity and in vivo tumor targeting, and for its non-competing character with trastuzumab and pertuzumab for HER2 I-2Rs15d will not be able to bind either. In certain tumors, a fraction of HER2 molecules are proteolytically shed, resulting in for example truncated p95HER2 which is found in about 10-30% of HER2-overexpressing tumors (31, 38) . With the proposed technology, low radioactive dose *I-2Rs15d will allow the selection of patients who still have sufficient intact HER2 to be eligible for therapeutic  131 I-2Rs15d. Also, as 2Rs15d binds HER2 domain I, which is most distant from the cell membrane, it might be less influenced by epitope masking agents, or by domain IV mutations that prevent trastuzumab and T-DM1 from binding HER2 (28, (31) (32) (33) (34) . As steric interference by MUC4 can play an important role in this process, we therefore focused on this mechanism. Recently it was shown that TNF can induce MUC4 expression in HER2-positive breast and gastric cancer cells (38) . Moreover, they observed a strong association between MUC4-positive tumors and a shorter DFS in patients receiving adjuvant trastuzumab-based treatment (39) . We show here that  131 I-2Rs15d binds four times higher to JIMT-1 compared to 
131
I-trastuzumab, while binding to trastuzumab-responsive BT474/M1 was similar for both compounds ( Fig. 1F-G) . In contrast, the trastuzumab-competing sdAb 2Rb17c outperformed trastuzumab on the same cell line, which implies that a smaller-sized sdAb was less hindered by the presence of MUC4. In addition, as the cytotoxic β --particles of 
We here showed that  131 I-2Rs15d binds specifically to HER2, and when injected i.v. in mice, it is eliminated from blood rapidly. High contrast micro-SPECT/CT images delineated tumors as early as 1h p.i. in two distinct HER2 + mouse models. The clearance of 
I-2Rs15d from kidneys was faster than ever observed for this sdAb (18, 20, 21, 36, 37 LuDTPA-2Rs15d, in tandem with 150 mg/kg Gelofusin treatment, to kidneys (10 Gy) (21) . Analysis of the radioactivity present in urine revealed the increasing presence of radiolabeled metabolites, confirming that 
ISGMIB indeed gives rise to rapidly clearing catabolites after renal filtration (23) . This is an important benefit compared to the previously used radiometal chemistry that led to retained radioactivity in kidneys (18, 19, 21) .
The tumor uptake for 
I-2Rs15d was lower than that obtained with *I-5F7GGC sdAb.
Here, absorbed doses of 45 and 30 Gy were delivered to BT474/M1 tumors from 37 MBq (in two independent experiments), and about 18 and 16 Gy to kidneys (25) . The difference in tumor uptake between 2Rs15d and 5F7GGC might be attributable to the fact that they target different HER2 epitopes (25) . Because *ISGMIB traps radioiodine intracellularly, this effect is more pronounced for highly internalizing sdAbs like 5F7GGC than for moderately internalizing I-2Rs15d were alive at the end of the study, confirming that repeated co-administration of
I-2Rs15d does not negatively affect therapeutic outcome ( Fig. 5D-E) . It is important to note that this trastuzumab-responsive SKOV-3.IP1 model is very aggressive and is defined by rapid disease progression (29) . Mice were treated with an optimized trastuzumab treatment over 5
weeks and progressed after treatment termination. We anticipated therefore that  long-term studies of renal toxicity will be required (41) . In addition, therapeutic efficacy of
I-2Rs15d will be further assessed in the trastuzumab-resistant JIMT-1 model, which is targetable by 2Rs15d but not by trastuzumab. With these goals in mind, we are currently upscaling the radiochemical process to obtain higher radioactive levels of  131 I-2Rs15d.
-Particle emitting isotopes might achieve higher therapeutic absorbed doses to tumors compared to β --particles. However, as their path length is shorter, the cell killing efficiency is more influenced by receptor heterogeneity (42) . Consequently, -particle therapy might be more suited in a micrometastatic setting. In line with antibody-drug conjugates, sdAbs have been successfully conjugated with cytotoxic payloads like DM1 or PE38-toxin, showing efficient tumor growth control without systemic toxicity (43) (44) (45) . However, selecting highly internalizing sdAbs will be mandatory to induce significant cytotoxic effects. In addition, receptor heterogeneity might affect therapeutic outcome, which can be effectively addressed with a cytotoxic agent such as 131 I with a multi-cellular range of action.
To our knowledge, this is the first study to describe a theranostic radiolabeled sdAb suitable for clinical translation.  
